RT Journal Article
SR Electronic
T1 Peritoneal Spread of Low-grade Appendiceal Tumours – 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5569
OP 5575
DO 10.21873/anticanres.15370
VO 41
IS 11
A1 APOORVA RAO
A1 JASMINE MUI
A1 SHOMA BARAT
A1 AMER A. MATAR
A1 NAYEF ALZAHRANI
A1 DAVID L. MORRIS
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5569.abstract
AB Background/Aim: While controversial, cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) and early postoperative intra-peritoneal chemotherapy (EPIC) remains the mainstay of treatment for low grade appendiceal neoplasm with pseudomyxoma peritonei (PMP). Our study aimed to investigate the difference in survival when administering HIPEC alone vs. HIPEC + EPIC. Additionally, we examined whether the duration of EPIC affects survival. Patients and Methods: We compared the difference in survival in 238 patients who underwent CRS + HIPEC alone vs. CRS + HIPEC/EPIC combination for low grade appendiceal cancer. We also compared short course (1-2 days) vs. long course (3-5 days) of EPIC. Results: HIPEC/EPIC combination group (n=179) showed a significantly better 5-year survival of 95% compared to 71% in HIPEC alone (n=59). There was no statistically significant difference in 5-year survival between short course (n=22) and long course of EPIC (n=157). Conclusion: Combined use of HIPEC and EPIC improves 5-year survival in low-grade appendiceal neoplasm. Two days of EPIC are sufficient.